Publications by authors named "Janet Oblinger"

Claim this Profile
C
Combining brigatinib with mTOR inhibition to effectively treat NF2-SWN-associated and sporadic NF2-deficient meningiomas.
Long-Sheng Chang, Janet L Oblinger, Lai Man Natalie Wu, Cecelia Miller, Sarah S Burns

Cancer Res Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell and Spatial Omics Reveals Region-Specific Plasticity and Therapeutic Vulnerabilities in Metastatic High-Risk Neuroblastoma.
Lai Man Natalie Wu, Janet L Oblinger, Dazhuan Xin, Rohit Rao, Feng Zhang

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model.
Simeng Lu, Zhenzhen Yin, Limeng Wu, Yao Sun, Jie Chen, Janet L Oblinger

bioRxiv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor effects of the eIF4A inhibitor didesmethylrocaglamide and its derivatives in human and canine osteosarcomas.
Janet L Oblinger, Jack Wang, Georgia D Wetherell, Garima Agarwal, Tyler A Wilson

Sci Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
Long-Sheng Chang, Janet L Oblinger, Abbi E Smith, Marc Ferrer, Steven P Angus

PLoS One· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor Effects of the eIF4A Inhibitor Didesmethylrocaglamide and Its Derivatives in Human and Canine Osteosarcomas.
Janet Oblinger, Jack Wang, Georgia Wetherell, Garima Agarwal, Tyler Wilson

Res Sq· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in -deficient models.
Srirupa Bhattacharyya, Janet L Oblinger, Roberta L Beauchamp, Lili Kosa, Francis Robert

Neurooncol Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
Srirupa Bhattacharyya, Janet L Oblinger, Roberta L Beauchamp, Zhenzhen Yin, Serkan Erdin

Neuro Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.
D Bradley Welling, Katharine A Collier, Sarah S Burns, Janet L Oblinger, Edina Shu

Laryngoscope Investig Otolaryngol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments.
Anusha Amaravathi, Janet L Oblinger, D Bradley Welling, A Douglas Kinghorn, Long-Sheng Chang

Front Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.
Long-Sheng Chang, Janet L Oblinger, Sarah S Burns, Jie Huang, Larry W Anderson

Mol Cancer Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Steven P Angus, Janet L Oblinger, Timothy J Stuhlmiller, Patrick A DeSouza, Roberta L Beauchamp

Neuro Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
Janet L Oblinger, Sarah S Burns, Jie Huang, Li Pan, Yulin Ren

Exp Neurol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
Janet L Oblinger, Sarah S Burns, Elena M Akhmametyeva, Jie Huang, Li Pan

Neuro Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.
Samuel A Spear, Sarah S Burns, Janet L Oblinger, Yulin Ren, Li Pan

Otol Neurotol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
Sarah S Burns, Elena M Akhmametyeva, Janet L Oblinger, Matthew L Bush, Jie Huang

Cancer Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of vestibular schwannoma cells with ErbB inhibitors.
Matthew L Bush, Sarah S Burns, Janet Oblinger, Sholpan Davletova, Long-Sheng Chang

Otol Neurotol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.
Abraham Jacob, Janet Oblinger, Matthew L Bush, Victoria Brendel, Griffin Santarelli

Laryngoscope· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Matthew L Bush, Janet Oblinger, Victoria Brendel, Griffin Santarelli, Jie Huang

Neuro Oncol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1.
Guolin Chai, Ning Liu, Junrong Ma, Hua Li, Janet L Oblinger

Cancer Sci· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurotrophin-3 deficient Schwann cells impair nerve regeneration.
Zarife Sahenk, Janet Oblinger, Chris Edwards

Exp Neurol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Domain-dependent modulation of PDGFRbeta by ganglioside GM1.
Janet L Oblinger, Cynthia L Boardman, Allan J Yates, Richard W Burry

J Mol Neurosci· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis